HEALTH CATALYST INC (HCAT) Stock Price, Quote, News and Overview
NASDAQ:HCAT - Nasdaq - US42225T1079 - Common Stock - Currency: USD
HCAT Quote, Performance and Key Statistics
5.23
-0.16 (-2.97%)
The current stock price of HCAT is 5.23 USD. In the past month the price decreased by -9.67%. In the past year, price decreased by -32.78%.
HCAT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 36.13 | 36.66B | ||
| DOCS | DOXIMITY INC-CLASS A | 56.54 | 13.58B | ||
| WAY | WAYSTAR HOLDING CORP | N/A | 7.26B | ||
| CERT | CERTARA INC | 33.77 | 2.12B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.98B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 15.03 | 1.83B | ||
| SDGR | SCHRODINGER INC | N/A | 1.65B | ||
| PHR | PHREESIA INC | N/A | 1.64B | ||
| EVH | EVOLENT HEALTH INC - A | 15.8 | 1.22B | ||
| HSTM | HEALTHSTREAM INC | 50.58 | 999.88M | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 966.46M | ||
| DH | DEFINITIVE HEALTHCARE CORP | 14.47 | 762.50M |
Related stock screener links
About HCAT
Company Profile
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. The company is headquartered in South Jordan, Utah. The company went IPO on 2019-07-25. The Company’s solution comprises its cloud-based data and analytics platform, software applications, and professional services expertise. The firm operates through two segments: Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and is focused primarily on contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its customers to fully configure and utilize the benefits of its technology offerings. Its clients include academic medical centers, integrated delivery networks, community hospitals, physician practices, health insurers, and others.
Company Info
HEALTH CATALYST INC
10897 South River Front Parkway, #300
South Jordan UTAH 84121 US
CEO: Daniel Burton
Employees: 1300
Company Website: https://www.healthcatalyst.com/
Investor Relations: https://ir.healthcatalyst.com/investor-relations
Phone: 18017086800
HEALTH CATALYST INC / HCAT FAQ
What is the stock price of HEALTH CATALYST INC today?
The current stock price of HCAT is 5.23 USD. The price decreased by -2.97% in the last trading session.
What is the ticker symbol for HEALTH CATALYST INC stock?
The exchange symbol of HEALTH CATALYST INC is HCAT and it is listed on the Nasdaq exchange.
On which exchange is HCAT stock listed?
HCAT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HEALTH CATALYST INC stock?
20 analysts have analysed HCAT and the average price target is 9.99 USD. This implies a price increase of 90.97% is expected in the next year compared to the current price of 5.23. Check the HEALTH CATALYST INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HEALTH CATALYST INC worth?
HEALTH CATALYST INC (HCAT) has a market capitalization of 318.25M USD. This makes HCAT a Small Cap stock.
How many employees does HEALTH CATALYST INC have?
HEALTH CATALYST INC (HCAT) currently has 1300 employees.
What are the support and resistance levels for HEALTH CATALYST INC (HCAT) stock?
HEALTH CATALYST INC (HCAT) has a resistance level at 5.9. Check the full technical report for a detailed analysis of HCAT support and resistance levels.
Is HEALTH CATALYST INC (HCAT) expected to grow?
The Revenue of HEALTH CATALYST INC (HCAT) is expected to grow by 4.11% in the next year. Check the estimates tab for more information on the HCAT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HEALTH CATALYST INC (HCAT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HCAT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HCAT, evaluating the profitability, health, valuation and growth aspects
- HEALTH CATALYST INC (HCAT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HEALTH CATALYST INC (HCAT) Sales and EPS estimates to see what analysts future expectations are.
- HEALTH CATALYST INC (HCAT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HEALTH CATALYST INC (HCAT) Insider and Institutional Ownership to learn about the owners and their transactions.
- HEALTH CATALYST INC (HCAT) Stock Chart to make your own analysis
- HEALTH CATALYST INC (HCAT) Latest news and press-releases to stay up to date.
Does HEALTH CATALYST INC (HCAT) stock pay dividends?
HCAT does not pay a dividend.
When does HEALTH CATALYST INC (HCAT) report earnings?
HEALTH CATALYST INC (HCAT) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of HEALTH CATALYST INC (HCAT)?
The PE ratio for HEALTH CATALYST INC (HCAT) is 20.12. This is based on the reported non-GAAP earnings per share of 0.26 and the current share price of 5.23 USD. Check the full fundamental report for a full analysis of the valuation metrics for HCAT.
What is the Short Interest ratio of HEALTH CATALYST INC (HCAT) stock?
The outstanding short interest for HEALTH CATALYST INC (HCAT) is 3.39% of its float. Check the ownership tab for more information on the HCAT short interest.
HCAT Technical Analysis
HCAT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HCAT. HCAT has a bad profitability rating. Also its financial health evaluation is rather negative.
HCAT Financial Highlights
Over the last trailing twelve months HCAT reported a non-GAAP Earnings per Share(EPS) of 0.26. The EPS increased by 225% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.73% | ||
| ROE | -22.29% | ||
| Debt/Equity | 0.32 |
HCAT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to HCAT. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of 109.96% and a revenue growth 4.11% for HCAT